Microglial activation and amyloid deposition in mild cognitive impairment

Background: Activated microglia may play a role in the pathogenesis of Alzheimer disease (AD) as they cluster around beta-amyloid (Aβ) plaques. They are, therefore, a potential therapeutic target in both AD and its prodrome amnestic mild cognitive impairment (MCI). Objective: To characterize in vivo with 11C-(R)-PK11195 and 11C-PIB PET the distribution of microglial activation and amyloid deposition in patients with amnestic MCI. Methods: Fourteen subjects with MCI had 11C-(R)-PK11195 and 11C-PIB PET with psychometric tests. Results: Seven out of 14 (50%) patients with MCI had increased cortical 11C-PIB retention (p < 0.001) while 5 out of 13 (38%) subjects with MCI showed increased 11C-(R)-PK11195 uptake. The MCI subgroup with increased 11C-PIB retention also showed increased cortical 11C-(R)-PK11195 binding (p < 0.036) though this increase only remained significant in frontal cortex after a correction for multiple comparisons. There was no correlation between regional levels of 11C-(R)-PK11195 and 11C-PIB binding in individual patients with MCI: only three of the five MCI cases with increased 11C-(R)-PK11195 binding had increased levels of 11C-PIB retention. Conclusions: Our findings indicate that, while amyloid deposition and microglial activation can be detected in vivo in around 50% of patients with mild cognitive impairment (MCI), these pathologies can occur independently. The detection of microglial activation in patients with MCI suggests that anti-inflammatory therapies may be relevant to the prevention of AD.

• Publication year

  2009

• Venue

  Neurology

• Publication date

  2009-01-02

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/01.wnl.0000338622.27876.0dPMID 19122031PMCID PMC2817573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PET imaging of amyloid deposition in patients with mild cognitive impairment.

  2008cited by this paper
• Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease

  2008cited by this paper
• Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients.

  2008cited by this paper
• Imaging β-amyloid burden in aging and dementia

  2007cited by this paper
• Amyloid, hypometabolism, and cognition in Alzheimer disease

  2007cited by this paper
• Own your practice. It goes without saying that your future is of great value.

  2007cited by this paper
• A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195

  2007cited by this paper
• Reference and target region modeling of [11C]-(R)-PK11195 brain studies.

  2007cited by this paper
• Imaging beta-amyloid burden in aging and dementia.

  2007cited by this paper
• PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment

  2007cited by this paper
• The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: implications for PET imaging.

  2007cited by this paper
• Neuropathologic substrate of mild cognitive impairment.

  2006cited by this paper
• In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.

  2006cited by this paper
• [11C]PIB in a nondemented population

  2006cited by this paper
• Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study

  2006cited by this paper
• Neuropathologic features of amnestic mild cognitive impairment.

  2006cited by this paper
• Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B

  2005cited by this paper
• Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

  2005cited by this paper
• Microglia and neuroprotection: implications for Alzheimer's disease.

  2005cited by this paper
• In vivo detection of microglial activation in frontotemporal dementia

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease.

  2004cited by this paper
• Assessment of Neuroinflammation and Microglial Activation in Alzheimer’s Disease with Radiolabelled PK11195 and Single Photon Emission Computed Tomography

  2003cited by this paper
• The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component

  2003cited by this paper
• Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe

  2003cited by this paper
• Current concepts in mild cognitive impairment.

  2001cited by this paper
• Inflammation, autotoxicity and Alzheimer disease.

  2001cited by this paper
• Estimation of the number of "true" null hypotheses in multivariate analysis of neuroimaging data.

  2001cited by this paper
• Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude

  2001cited by this paper
• In-vivo measurement of activated microglia in dementia.

  2001cited by this paper
• Microglia, amyloid and dementia in alzheimer disease. A correlative study.

  2000cited by this paper
• The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.

  2000cited by this paper
• Microglial activation induced by factor(s) contained in sera from Alzheimer‐related ApoE genotypes

  1998cited by this paper
• The cerebellum in Alzheimer's disease.

  1997cited by this paper
• Slow Degradation of Aggregates of the Alzheimer’s Disease Amyloid β-Protein by Microglial Cells*

  1997cited by this paper
• Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.

  1997cited by this paper
• Scavenging of Alzheimer's amyloid β‐protein by microglia in culture

  1996cited by this paper
• PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease.

  1995cited by this paper
• Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats.

  1994cited by this paper
• Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease.

  1989cited by this paper
• Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain

  1989cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Genetic validation of ABI3 p.Ser209Phe variant and its effects on early brain pathology in asymptomatic elderly individuals.

  2026cites this paper
• Microglial activation is raised in preclinical Alzheimer’s disease and associated with covert memory impairment

  2026cites this paper
• Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives

  2025cites this paper
• A Landmark Multiyear Study of Alzheimer Disease: Integrating [18F]FEPPA PET Imaging With 12 Clinical Assessments for Comprehensive Disease Profiling

  2025cites this paper
• The association between periodontal disease, dementia, and mild cognitive Impairment: Assessing the contribution of sleep disturbances and sleep disorders.

  2025cites this paper
• Demyelination-derived lysophosphatidylserine promotes microglial dysfunction and neuropathology in a mouse model of Alzheimer’s disease

  2025cites this paper
• Amyloid β-Induced Inflammarafts in Alzheimer’s Disease

  2025cites this paper
• Direct and indirect role of non-coding RNAs in company with amyloid and tau protein in promoting neuroinflammation in post-ischemic brain neurodegeneration

  2025cites this paper
• The relation between neuroinflammation, amyloid-β load, grey matter loss and brain activity in visual object recognition regions in Alzheimer's Disease

  2025cites this paper
• Exploring the diagnostic potential of EEG theta power and interhemispheric correlation of temporal lobe activities in Alzheimer's Disease through random forest analysis

  2025cites this paper
• Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease

  2025cites this paper
• Immunosenescence and the Geriatric Giants: Molecular Insights into Aging and Healthspan

  2025cites this paper
• The mitochondrial Translocator protein (TSPO) in Alzheimer's Disease: Therapeutic and Immunomodulatory Functions.

  2024cites this paper
• Non-canonical Pathways Associated to Amyloid Beta and Tau Protein Dyshomeostasis in Alzheimer's disease: a narrative review.

  2024cites this paper
• Brain-Immune interactions: Implication for Cognitive impairments in Alzheimer's Disease and autoimmune disorders.

  2024cites this paper
• Neutrophil to lymphocyte ratio in Alzheimer’s disease: A systematic review and meta-analysis

  2024cites this paper
• Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects

  2024cites this paper
• Erjingpill bionic cerebrospinal fluid alleviates LPS-induced inflammatory response in BV2 cells by inhibiting glycolysis via mTOR.

  2024cites this paper
• FAAH Inhibition Counteracts Neuroinflammation via Autophagy Recovery in AD Models

  2024cites this paper
• Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer’s disease

  2024cites this paper
• Tetramerization of PKM2 Alleviates Traumatic Brain Injury by Ameliorating Mitochondrial Damage in Microglia

  2024cites this paper
• NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

  2024cites this paper
• Yishen Huazhuo decoction regulates microglial polarization to reduce Alzheimer's disease-related neuroinflammation through TREM2

  2024cites this paper
• Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer’s disease

  2024cites this paper
• Systemic inflammation in relation to exceptional memory in the Long Life Family Study (LLFS)

  2024cites this paper
• Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease.

  2024cites this paper
• Synergism of ApoE4 and systemic infectious burden is mediated by the APOE‐NLRP3 axis in Alzheimer's disease

  2024cites this paper
• Alzheimer’s Disease and Neurosyphilis: Meaningful Commonalities and Differences of Clinical Phenotype and Pathophysiological Biomarkers

  2023cites this paper
• Emerging Roles of Cells and Molecules of Innate Immunity in Alzheimer’s Disease

  2023cites this paper
• Transferrin-Conjugated Melittin-Loaded L-Arginine-Coated Iron Oxide Nanoparticles for Mitigating Beta-Amyloid Pathology of the 5XFAD Mouse Brain

  2023cites this paper
• Microglia contribute to cognitive decline in hypercholesterolemic LDLr−/− mice

  2023cites this paper
• Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets

  2023cites this paper
• Peripheral immune cell imbalance is associated with cortical beta-amyloid deposition and longitudinal cognitive decline

  2023cites this paper
• Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration

  2023cites this paper
• Prevention of Alzheimer Pathology by Blocking Neuregulin Signaling on Microglia

  2023cites this paper
• The effect of the tumour necrosis factor-alpha-inhibitor etanercept on microglial activation patients with mild cognitive impairment—a PET study

  2023cites this paper
• Molecular Imaging of Neuroinflammation in Alzheimer's Disease and Mild Cognitive Impairment.

  2023cites this paper
• APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly

  2023cites this paper
• A Systematic Review on Dementia and Translocator Protein (TSPO): When Nuclear Medicine Highlights an Underlying Expression

  2023cites this paper
• Textural properties of microglial activation in Alzheimer’s disease as measured by (R)-[11C]PK11195 PET

  2023cites this paper
• Molecular and environmental contributors to neurological complications in sickle cell disease

  2023cites this paper
• Quercus acuta Thunb. Suppresses LPS-Induced Neuroinflammation in BV2 Microglial Cells via Regulating MAPK/NF-κB and Nrf2/HO-1 Pathway

  2022cites this paper
• Inflammation-Related microRNAs-146a and -155 Are Upregulated in Mild Cognitive Impairment Subjects Among Older Age Population in Montenegro

  2022cites this paper
• Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer’s disease and mild cognitive impairment

  2022cites this paper
• APOE ε4 gene dose effect on imaging and blood biomarkers of glial reactivity and β-amyloid pathology

  2022cites this paper
• Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: An update

  2022cites this paper
• Microglial Endocannabinoid Signalling in AD

  2022cites this paper
• Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview.

  2022cites this paper
• Spatiotemporal patterns of gliosis and neuroinflammation in presenilin 1/2 conditional double knockout mice

  2022cites this paper
• The Impact of Systemic Inflammation on Alzheimer’s Disease Pathology

  2022cites this paper
• The impact of physical activity on blood inflammatory cytokines and neuroprotective factors in individuals with mild cognitive impairment: a systematic review and meta-analysis of randomized-controlled trials

  2022cites this paper
• LOTUS suppresses amyloid β-induced dendritic spine elimination through the blockade of amyloid β binding to PirB

  2022cites this paper
• CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers

  2022cites this paper
• Intranasal interferon-beta alleviates anxiety and depressive-like behaviors by modulating microglia polarization in an Alzheimer's disease model.

  2022cites this paper
• The Hidden Role of Non-Canonical Amyloid β Isoforms in Alzheimer’s Disease

  2022cites this paper
• PET Imaging of Fructose Metabolism in a Rodent Model of Neuroinflammation with 6-[18F]fluoro-6-deoxy-D-fructose

  2022cites this paper
• Oxygen Sensing and Signaling in Alzheimer’s Disease: A Breathtaking Story!

  2021cites this paper
• Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development

  2021cites this paper
• Thioperamide attenuates neuroinflammation and cognitive impairments in Alzheimer's disease via inhibiting gliosis.

  2021cites this paper
• The effect of reminder focused positive psychiatry suicide safety (RFPP-S) on COVID-19 related PTSD with PGD

  2021cites this paper
• The role of resistance exercise training & IGF-1 signaling in the amelioration of mild cognitive impairment in female Wistar rats

  2021cites this paper
• Intestinal Barrier Dysfunction Exacerbates Neuroinflammation via the TLR4 Pathway in Mice With Heart Failure

  2021cites this paper
• Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers

  2021cites this paper
• PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research

  2021cites this paper
• Microglia as therapeutic targets after neurological injury: strategy for cell therapy

  2021cites this paper
• Renal Denervation Attenuates Neuroinflammation in the Brain by Regulating Gut-Brain Axis in Rats With Myocardial Infarction

  2021cites this paper
• Mapping of Translocator Protein (18 kDa) in Peripheral Sterile Inflammatory Disease and Cancer through PET Imaging.

  2021cites this paper
• Biomarkers used in Alzheimer's Disease diagnosis, treatment, and prevention.

  2021cites this paper
• In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue

  2021cites this paper
• Neuroinflammation in Alzheimer’s Disease

  2021cites this paper
• Resistance-exercise training attenuates LPS-induced astrocyte remodeling and neuroinflammatory cytokine expression in female Wistar rats.

  2021cites this paper
• Brain Metabolism and Microglia Activation in Mild Cognitive Impairment: A Combined [18F]FDG and [11C]-(R)-PK11195 PET Study

  2021cites this paper
• Advances in Brain Amyloid Imaging.

  2021cites this paper
• Investigating the Spatial Associations Between Amyloid-β Deposition, Grey Matter Volume, and Neuroinflammation in Alzheimer’s Disease

  2021cites this paper
• Central Nervous System Molecular Imaging

  2021cites this paper
• Mitochondrial Deficits With Neural and Social Damage in Early-Stage Alzheimer’s Disease Model Mice

  2021cites this paper
• Alzheimer’s Disease

  2021cites this paper
• Decreasing auditory input induces neurogenesis impairment in the hippocampus

  2021cites this paper
• Cytokine Signalling at the Microglial Penta-Partite Synapse

  2021cites this paper
• Detection of Alzheimer’s disease-related neuroinflammation by a PET ligand selective for glial versus vascular translocator protein

  2021cites this paper
• ATP-sensitive potassium channel subunits in the neuroinflammation: novel drug targets in neurodegenerative disorders.

  2021cites this paper
• Transnasal transplantation of human induced pluripotent stem cell‐derived microglia to the brain of immunocompetent mice

  2021cites this paper
• Relationship between tau, neuroinflammation and atrophy in Alzheimer's disease: The NIMROD study

  2021cites this paper
• Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

  2020cites this paper
• Motor dysfunction in mild cognitive impairment as tested by kinematic analysis and transcranial magnetic stimulation.

  2020cites this paper
• PET Neuroimaging in Dementia Conditions

  2020cites this paper
• SPECT/PET Findings in Dementia with Lewy Bodies

  2020cites this paper
• Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases

  2020influential citation
• PET Imaging of Translocator Protein Expression in Neurological Disorders

  2020cites this paper
• PET imaging of neuroinflammation in neurological disorders.

  2020cites this paper
• Associations of Subsyndromal Symptomatic Depression with Cognitive Decline and Brain Atrophy in Elderly Individuals without Dementia: A Longitudinal Study.

  2020cites this paper
• Chlorzoxazone exhibits neuroprotection against Alzheimer's disease by attenuating neuroinflammation and neurodegeneration in vitro and in vivo.

  2020cites this paper
• Differential Expression and miRNA–Gene Interactions in Early and Late Mild Cognitive Impairment

  2020cites this paper
• Neuroimaging of Diseases Causing Dementia.

  2020cites this paper
• Multiple inflammatory profiles of microglia and altered neuroimages in APP/PS1 transgenic AD mice.

  2020cites this paper
• Inhibition of Histamine H3 receptor Attenuates Neuroinflammation and Cognitive Impairments in Alzheimer’s Disease via activating CREB Pathway

  2020cites this paper
• Blood-based biomarkers of Alzheimer's disease: the long and winding road.

  2020cites this paper
• A Review and Hypothesized Model of the Mechanisms That Underpin the Relationship Between Inflammation and Cognition in the Elderly

  2019cites this paper
• Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development

  2019cites this paper
• Low-dose ladostigil for mild cognitive impairment

  2019cites this paper